RxDoctor Payments Data

Charulata Mehta, MD

Internal Medicine · Columbia, MDNPI 1255490686

Payments from drug & device makers

$1,361in general payments, 2019–2025

Across 18 payments — averaging $75.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$607
  • AstraZeneca$230
  • Boehringer Ingelheim$110
  • Eisai Inc.$110
  • Mylan Specialty L.p.$110
  • AbbVie$100
  • plus $94 from 1 others

What the payments were for

  • Food & beverage$1,361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,361 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$32,259
Medicare patients
139
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$8,926
FarxigaDapagliflozin Propanediol11$5,440
Levothyroxine Sodium54$756
Rosuvastatin Calcium26$674
Nifedipine ErNifedipine33$641
Valsartan14$618
Metoprolol Succinate58$545
Fenofibric AcidFenofibric Acid (Choline)16$522
Atorvastatin Calcium47$520
Oxybutynin Chloride ErOxybutynin Chloride11$490
Pantoprazole Sodium30$324
Amlodipine Besylate48$310
Losartan Potassium33$234
Metformin Hcl ErMetformin Hcl12$233
Metformin Hcl42$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$110$8,92614 claims
AstraZenecaFarxiga$230$5,44011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →